chrisvoncsefalvay/vaers-outcomes huggingface dataset:
pressure on their head; memory loss when thinking at words; Vertigo; Missed dose; Mild fatigue; mild headache; Brain fog, cloud feeling, foggy feeling; high feeling; This spontaneous case was reported by a consumer and describes the occurrence of FEELING ABNORMAL (Brain fog, cloud feeling, foggy feeling), EUPHORIC MOOD (high feeling), HEAD DISCOMFORT (pressure on their head), APHASIA (memory loss when thinking at words) and VERTIGO (Vertigo) in a 23-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 026L20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 07-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 07-Jan-2021, the patient experienced FEELING ABNORMAL (Brain fog, cloud feeling, foggy feeling), EUPHORIC MOOD (high feeling), FATIGUE (Mild fatigue) and HEADACHE (mild headache). On an unknown date, the patient experienced HEAD DISCOMFORT (pressure on their head), APHASIA (memory loss when thinking at words), VERTIGO (Vertigo) and PRODUCT DOSE OMISSION ISSUE (Missed dose). The patient was treated with AMFETAMINE ASPARTATE, AMFETAMINE SULFATE, DEXAMFETAMINE SACCHARATE, DEXAMFETAMINE SULFATE (ADDERALL) for Adverse event, at a dose of 5 mg; CAFFEINE on 13-Jan-2021 for Headache, at an unspecified dose and frequency and IBUPROFEN (ADVIL [IBUPROFEN]) on 13-Jan-2021 for Adverse event, at an unspecified dose and frequency. At the time of the report, FEELING ABNORMAL (Brain fog, cloud feeling, foggy feeling), HEAD DISCOMFORT (pressure on their head), APHASIA (memory loss when thinking at words) and VERTIGO (Vertigo) had not resolved, EUPHORIC MOOD (high feeling), FATIGUE (Mild fatigue) and HEADACHE (mild headache) had resolved and PRODUCT DOSE OMISSION ISSUE (Missed dose) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Additional treatment for the events included steroids and Physical therapy.   This case was linked to MOD-2021-013493 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 09-Mar-2021: Additional information on events and treatment. On 23-Jun-2021: Significant Follow-up; Sender's Comments: Very limited information regarding this event/s has been provided at this time.  Further information has been requested.  .
This health authority case was initially received on 21-Apr-2016. The case report was received from a Health Authority and concerns a 49 year old female patient who had no current illness and no medical history. Suspect drug(s), timing and conditions surrounding the onset of reaction(s)/event(s): The patient received AFLURIA on 02-Oct-2015 - unknown stop date, Batch no: U55906, Route of administration: Intramuscular, Dose: 0.5 ml, site: left arm. Additional suspect drug(s): No additional drugs suspected. Reaction(s)/event(s) and outcome: On an unknown date, after starting / treatment with AFLURIA, the patient experienced Numbness and Pain occurred in left arm (non serious, outcome: Not Recovered / Not Resolved) shortly after vaccination and continued to present (at the time of reporting). The patient did not report this to the pharmacist until 16-Feb-2016. Patient has yet to visit her physician to determine what might be the problem. Reporter's assessment: Non serious.
Information has been received from a physician referring to a 68 year old male patient with no drug reactions/allergies. On an unknown date the patient was vaccinated with a dose of ZOSTAVAX (strength, dose, frequency, route and lot# were unspecified) at an unspecified pharmacy. There was no concomitant medication reported. The patient called the physician on 06-APR-2015 to report that a rash developed on his right leg on the same day. The physician had not assessed the patient yet, however the patient would be seen by him later on 07-APR-2015. No treatment was given. No lab diagnostic studies was performed. At the time of reporting, the patient had not recovered from rash. The causality between adverse event and ZOSTAVAX was not provided. Additional information has been requested.
"Happens every time I see a needle". Diaphoretic and dizzy, but never passes out.
11/18/21: pt presents to ED with slurred speech and confusion for an hour  pt was worked upi with following note: ] "Acute ischemic stroke (HCC) Hypertension, unspecified type Diagnosis management comments: Patient presents to the emergency department slurred speech.  Brain attack protocol was initiated.  CT the brain shows no acute intracranial findings.  Chest x-ray shows limited evaluation with no radiographic evidence of acute cardiopulmonary disease.  CTA head and neck shows1. No hemodynamically significant stenosis at the extracranial carotid or vertebral arteries.  2. No intracranial large vessel occlusion or flow-limiting stenosis.  CBC shows a normal white count and hemoglobin 11.7.  INR is normal.  Chemistry shows a glucose of 124 otherwise normal.  Troponin is normal.  Covid is negative.  Brain attack protocol was initiated.  The eICU neurologist evaluated the patient and felt that he should get TPA.  She discussed with wife at bedside and consulted for the TPA.  Patient and wife did agree to the TPA. " - TPA given 11/18/21 14:05
Developed moderate to severe Raynauds in bilateral fingers with cold exposure.  Live in warm climate so Nov was first cold exposure from vaccine. Has continued to be problematic 1-4 times per week, quite painful.
COVID-19; COVID-19; This is a spontaneous report received from a contactable consumer. The reporter is the patient. A 64-year-old female patient (not pregnant) received bnt162b2, bnt162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 14Sep2022 as dose 5 (booster), single (Lot number: GH9694) at the age of 63 years, in right arm for covid-19 immunisation; bnt162b2 (BNT162B2), on 21Feb2021 at 15:30 as dose 1, single (Lot number: EN6198), in left arm, on 14Mar2021 at 14:45 as dose 2, single (Lot number: EN6206), in left arm, on 25Sep2021 as dose 3 (booster), single (Batch/Lot number: unknown) and on 15Apr2022 as dose 4 (booster), single (Lot number: FK9895) for covid-19 immunisation. The patient's relevant medical history included: "High cholesterol" (unspecified if ongoing); "Known allergies: Milk" (unspecified if ongoing). The patient's concomitant medications were not reported. Patient received Paxlovid for COVID-19 Treatment from 15Sep2023 to 18Sep2023. Outcome of the events was unknown.   The information on the batch/lot number for bnt162b2 has been requested and will be submitted if and when received.
Arm hurt so bad; patient couldn't move the arm, could not lift her arm for 3 or 4 days.; This is a spontaneous report from a contactable consumer or other non hcp. A 49-years-old female patient received BNT162B2, (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: Solution for injection, lot number: (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: Solution for injection, lot number: ER8727) as DOSE 1, SINGLE, via an unspecified route of administration, administered in Arm Left on 25Mar2021 between 10 to 11pm in the morning for covid-19 immunization. The patient medical history included ongoing inflammation due to allergies. The patient had cancer last year, did not have chemotherapy and doctors encouraged the caller to get Vaccine. The patient concomitant medications were not reported. The patient previously took Pneumonia and flu vaccine. The patient did not have any other vaccinations within four weeks prior to the first administration date of the suspect vaccine. After receiving the first dose of vaccine on 25Mar2021, the patient's arm hurt so bad (pain in extremity) and patient couldn't move the arm, mobility decreased on 25Mar2021. The patient stated that the arm was still hurting. The patient reported that certain ways the arm hurt more. It definitely hurt where the needle was put. The patient just recently had blood tests done and they were pretty normal. The clinical outcome of the event was Not recovered.  No follow-up attempts are possible. Information about lot/batch number cannot be obtained. No further information is expected.
received an expired dose; This case was reported by a pharmacist via call center representative and described the occurrence of expired vaccine used in a 32-year-old female patient who received Men ACWY-CRM NVS (Menveo) (batch number AMVA433A, expiry date 31st October 2021) for prophylaxis.   On 10th December 2021, the patient received Menveo. On 10th December 2021, unknown after receiving Menveo, the patient experienced expired vaccine used. On an unknown date, the outcome of the expired vaccine used was unknown.  Additional details were provided as follows: The age at vaccination was not reported. The patient received an expired dose of Menveo, which led to expired vaccine used. The reporter consented to follow up. This case was 1 of 6 linked cases, reported by same reporter for different patient.; Sender's Comments:  US-GLAXOSMITHKLINE-US2021261523:Same reporter US-GLAXOSMITHKLINE-US2021261527:Same reporter US-GLAXOSMITHKLINE-US2021261531:Same reporter US-GLAXOSMITHKLINE-US2021261529:Same reporter US-GLAXOSMITHKLINE-US2021261533:Same reporter
Hemorrhagic stroke, abnormal platelet count, petechai. Patient had my!triple CTs, MRI and angiogram after finding brain bleed. Once released home from brain bleed patient developed petechai, weakness, shortness of breath
Headache, Fever, NauseaVomiting,  FATIGUE Narrative: EMPLOYEE C/O SYMPTOMS OCCURING 2-3 HOURS POST VACCINATION. SYMPTOMS WERE REPORTED ON 1/27/21
Per physician has acute motor axonal neuropathy   .Motor weakness in both arms and hands .Was noticed two days after vaccination. Activies in daily living are greatly diminished
she had an episode of her heart racing for 10 minutes and she felt unwell and her heart is elevated still.; she had an episode of her heart racing for 10 minutes and she felt unwell.  She fell asleep right after to get away from the symptoms and this morning, she is still not well;; She fell asleep right after to get away from the symptoms and this morning, she is still not well; she feels clammy, cold and her heart is elevated still.; She fell asleep right after to get away from the symptoms and this morning, she is still not well; she feels clammy, cold and her heart is elevated still.; This is a spontaneous report from a contactable consumer (patient). A female patient of an unspecified age reported for herself who received bnt162b2 (Pfizer-BioNTech COVID-19 Vaccine, Solution for injection), dose 1 via an unspecified route of administration on 07May2021 12:00 Pm (Batch/Lot number was not reported) as DOSE 1, SINGLE for covid-19 immunisation. The patient medical history and concomitant medications were not reported. The patient had an episode of her heart racing for 10 minutes and she felt unwell. She fell asleep right after to get away from the symptoms and this morning, she was still not well; she feels clammy, cold and her heart is elevated still. The patient was concern about is this a side effect can it happen this far out. The patient disconnected abruptly as she did not like the answers what they had. It was unable to get her age. The clinical outcome of heart racing and felt unwell was not recovered and outcome of all other events was unknown.  The patient had a question that she had a side effect after the first dose of the vaccine. Should she get the second dose.  Response: As noted in the Fact Sheet for Recipients, patient should not get the Pfizer-BioNTech COVID-19 Vaccine if she had a severe allergic reaction after a previous dose of the vaccine or if she had a severe allergic reaction to any ingredient of the vaccine. The decision to receive the second dose for any other reason cannot be made by Pfizer. We refer her to speak to her healthcare provider about the risks of the vaccine compared to the risks of potentially not being fully protected against COVID-19 infection. Her healthcare provider knows her health situation and had access to information that he can better help inform this decision.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Pain in the arm; Headache; Blurred vision / He can see big letters but has difficulty reading small letters.; This is a spontaneous report from a contactable consumer (Patient).   A male patient of unspecified age received second dose of BNT162b2 (Pfizer-Biontech Covid19 vaccine, Lot number not reported), via an unspecified route of administration on 28Apr2021 as a single dose for COVID-19 immunisation. The patient medical history and concomitant medications were not reported. The patient received first dose of BNT162B2 (PFIZ-ER-BIONTECH COVID-19 VACCINE, Lot number: Not reported) on unknown date for covid-19 immunisation. On an unknown date in Apr2021, the patient developed, pain in the arm, headache and blurred vision. The patient can see big letters but has difficulty reading small letters. He lifts heavy stuff in his job. Patient wanted to know if he can take medications for pain (he is currently taking tylenol) to treat some of the side effects that he was presenting. At the time of this report event outcome was unknown.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
I received a single Shingrix vaccination well over a year ago.; This non-serious case was reported by a consumer via call center representative and described the occurrence of incomplete course of vaccination in a patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (received a single Shingrix vaccination well over a year ago).   On an unknown date, the patient did not receive the 2nd dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced incomplete course of vaccination (Verbatim: I received a single Shingrix vaccination well over a year ago.). The outcome of the incomplete course of vaccination was unknown.   Additional Information: GSK Receipt Date: 27-MAR-2023  Reporter asked what now. Start again with two, or just one. The patient received a single Shingrix vaccination well over a year ago and dose not yet which led to incomplete course of vaccination.
It is a nerve problem/ The vaccine affected the nerves of my face; Feels like it got worse/may be 60% feeling  Ok /leg on that same side felt maybe odd; Numbness in the lips, just a little; Left side of his face felt numb; Worried; Left side of his face felt warm; Face was oddly red, not sever, but red enough to notice; Left side of his face started tingling; This spontaneous case was reported by a consumer and describes the occurrence of NEURALGIA (It is a nerve problem/ The vaccine affected the nerves of my face), FEELING ABNORMAL (Feels like it got worse/may be 60% feeling  Ok /leg on that same side felt maybe odd), ANXIETY (Worried), FEELING HOT (Left side of his face felt warm) and ERYTHEMA (Face was oddly red, not sever, but red enough to notice) in a 42-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 028K21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 02-Jan-2022, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 02-Jan-2022, the patient experienced ANXIETY (Worried), FEELING HOT (Left side of his face felt warm), ERYTHEMA (Face was oddly red, not sever, but red enough to notice), PARAESTHESIA (Left side of his face started tingling) and HYPOAESTHESIA (Left side of his face felt numb). On 04-Jan-2022, the patient experienced HYPOAESTHESIA ORAL (Numbness in the lips, just a little). On 06-Jan-2022, the patient experienced FEELING ABNORMAL (Feels like it got worse/may be 60% feeling  Ok /leg on that same side felt maybe odd). On an unknown date, the patient experienced NEURALGIA (It is a nerve problem/ The vaccine affected the nerves of my face). On 02-Jan-2022, ERYTHEMA (Face was oddly red, not sever, but red enough to notice) had resolved. At the time of the report, NEURALGIA (It is a nerve problem/ The vaccine affected the nerves of my face), FEELING ABNORMAL (Feels like it got worse/may be 60% feeling  Ok /leg on that same side felt maybe odd) and ANXIETY (Worried) outcome was unknown and FEELING HOT (Left side of his face felt warm), PARAESTHESIA (Left side of his face started tingling), HYPOAESTHESIA ORAL (Numbness in the lips, just a little) and HYPOAESTHESIA (Left side of his face felt numb) was resolving.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications were reported. No treatment information was provided.  Patient stated that the time of vaccination was 3 'O' clock.
sore arm; This case was reported by a consumer via interactive digital media and described the occurrence of pain in arm in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine, the patient experienced pain in arm. On an unknown date, the outcome of the pain in arm was recovered/resolved.   It was unknown if the reporter considered the pain in arm to be related to Shingles vaccine.     Additional Information: GSK Receipt Date: 10-Apr-2022 Reporter's comments: This case was received from facebook page. This case was reported by the patient. The patient's doctor advised and the patient received Shingles vaccine. The patient experienced only a sore arm for a couple of days. The follow up would not possible as no contact details were available.; Sender's Comments:  US-GLAXOSMITHKLINE-US2022AMR064685:Same reporter
8 days after...arm tingling, itching with 4 inch red welt reappearing at vaccine injection site, left arm
woke up in the middle of the night to spinal  pain all the way from my throat to my  tailbone.  pain shooting down my right leg and twitching. chills...lasted over an hour.
sore arm; chills; itching on legs; rash on legs; This case was reported by a consumer and described the occurrence of pain in arm in a adult female patient who received Herpes zoster (Shingrix) for prophylaxis.   Concomitant products included Herpes zoster (Shingrix).   In November 2020, the patient received the 2nd dose of Shingrix. On an unknown date, less than 2 months after receiving Shingrix, the patient experienced pain in arm, chills, itchy legs and rash. Rechallenge with Shingrix was positive. On an unknown date, the outcome of the pain in arm, chills, itchy legs and rash were unknown.   It was unknown if the reporter considered the pain in arm, chills, itchy legs and rash to be related to Shingrix.  Additional details were provided as follows: The patient reported for herself. The age at vaccination was not reported. The patient received the 2nd dose of Shingrix and experienced sore arm, chills, itching on legs, and rash on legs. The reporter did not consent to follow-up. For tolerance of 1st dose refer case US2020AMR251388.; Sender's Comments:  US-GLAXOSMITHKLINE-US2020AMR251388:same reporter
12/30/2020: COVID Vaccine Pfizer-BioNTech dose 1 of 2 left arm. Acute onset left shoulder/arm pain 1-2 days later without inciting event (no trauma, no sports/weights), progressively worsening to severe next 2 days with onset of numbness and paresthesias in left upper arm and hand by 1/5/2021 seen at urgent care with dx: Cervical Neuropathy.  Follow-up cervical MRI 1/22/21 without significant canal or foraminal impingement.  Seen by Neurologist 2/3/2021, at that time  pain improved and localized to left shoulder joint area radiating under scapula and paresthesia resolved to numbness.  Physical exam findings: Absent triceps reflex, Left FDI atrophy, left hand finger extensor weakness, left abduction limited to 90 degrees.  Dx: Neurologic Amyotrophy (Parsonage Turner Syndrome); Complication of COVID vaccination.  Plan: EMG, NCS, Left shoulder MRI, labs pending.  PT OT ordered.  Rx: Nortriptyline, Medrol Dosepak.  F/U 2-3 months with neurology.
2 hours after injection, I had facial flushing which lasted about 2 hours.  2 Hours after injection, I had metallic taste in my mouth that lasted 3 days.  About 4 hours after injection I had  chills and headache which lasted about 24 hours, along with fatigue.   I also had night sweats for 3 days after injection.
first shingrix vaccine 8/8/2018 / has not yet received the second dose; shingles; This case was reported by a consumer via call center representative and described the occurrence of shingles in a 81-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   Co-suspect products included Herpes zoster (Shingrix) for prophylaxis.   On 8th August 2018, the patient received the 1st dose of Shingrix (intramuscular) .5 ml. On an unknown date, the patient received the 2nd dose of Shingrix. On 8th August 2018, more than 2 years after receiving Shingrix and not applicable after receiving Shingrix, the patient experienced shingles. On an unknown date, the patient experienced incomplete course of vaccination. On an unknown date, the outcome of the shingles and incomplete course of vaccination were unknown.   It was unknown if the reporter considered the shingles to be related to Shingrix.  Additional details were provided as follows: The reporter was the patient's wife. The age at vaccination was not reported for 1st dose. The age at vaccination was not applicable for 2nd dose. The patient had shingles since getting the first vaccine of Shingrix. Till the time of reporting, the patient did not receive 2nd dose of Shingrix, which led to incomplete course of vaccination. The reporter did not consent to follow up. This case was linked with case US2021254895, reported by same reporter for different patient.; Sender's Comments:  US-GLAXOSMITHKLINE-US2021254895:same reporter
According to the patient's mother, it's a large round raised circle at the injection site. The patient went to Urgent Care and was give an antibiotic shot and an oral antibiotic medication.
VERTIGO; This spontaneous case was reported by a consumer and describes the occurrence of VERTIGO (VERTIGO) in a 76-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 007M20A) for COVID-19 vaccination.     No Medical History information was reported.    On 26-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 27-Jan-2021, the patient experienced VERTIGO (VERTIGO). At the time of the report, VERTIGO (VERTIGO) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No relevant concomitant medications were reported. No treatment information was provided.
Right side of my face was numb and swollen. It sagged and I had no control of my muscles.